Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02020434 · ClinicalTrials.gov registry record · Phase 1
The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency
A Phase 1 study, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company).
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02020434 is a Phase 1 study that has completed, run by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company). The registered enrollment target is 32 participants.
The verdict
NCT02020434, a Phase 1 study, has completed, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
RPX7009(beta-lactamase inhibitor) is being studied in combination with carbapenem (RPX2014)to treat bacterial infections, including those due to multi-drug resistant bacteria.
Interventions
- DRUG RPX7009 and RPX2014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02020434
The ClinicalTrials.gov registry entry for NCT02020434 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RPX7009 and RPX2014 is the first listed.
NCT02020434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02020434 about?
NCT02020434 is a clinical study titled "The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency". RPX7009(beta-lactamase inhibitor) is being studied in combination with carbapenem (RPX2014)to treat bacterial infections, including those due to multi-drug resistant bacteria.
What is the current status of trial NCT02020434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02020434?
The interventions under investigation include: RPX7009 and RPX2014 (DRUG).
Who is sponsoring clinical trial NCT02020434?
This trial is sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.